Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)D. Waldschmidt, A. B. El-Khoueir,R. D. Kim,W. P. Harris,M. W. Sung,S. Iqbal, A. Zhang,K. Nakajima, P. R. GalleONCOLOGY RESEARCH AND TREATMENT（2020）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
